Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multi-Dose, Double-Blind, Double-Dummy, Active-Control, Randomized Study to Evaluate the Safety, Efficacy and Pharmacokinetic Profile of Two Dosing Regimens of Zabofloxacin for the Treatment of Community-Acquired Pneumonia of Moderate Severity

NCT01081964 is registered in ClinicalTrials.gov with IASO Pharma Inc. as lead sponsor.

NCT NCT01081964
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01081964 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multi-Dose, Double-Blind, Double-Dummy, Active-Control, Randomized Study to Evaluate the Safety, Efficacy and Pharmacokinetic Profile of Two Dosing Regimens of Zabofloxacin for the Treatment of Community-Acquired Pneumonia of Moderate Severity
Lead sponsor
IASO Pharma Inc.
Phase
Phase 2
Overall status
Terminated
Start date
March 31, 2010
Completion date
June 30, 2012
Enrollment
48 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

community acquired pneumonia